Key Points
- Director sale disclosed: Karimah Es Sabar sold 7,529 shares on April 2 at an average price of $32.00 under a pre‑arranged Rule 10b5‑1 plan, a $240,928 transaction reported in an SEC filing.
- Large insider selling this week: Es Sabar also sold 61,265 shares on March 31 and 53,735 on April 1, and the CFO sold 25,000 on March 31 — combined insider disposals total roughly 148,000 shares worth several million dollars, materially reducing insider holdings.
- Mixed market backdrop: Several analysts have raised price targets (e.g., Cantor $62, Piper $58; consensus avg ≈ $46), but the company missed Q4 EPS (-$0.62 vs. -$0.51), leaving sentiment divided despite bullish forecasts.
Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) Director Karimah Es Sabar sold 7,529 shares of the business's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total transaction of $240,928.00. Following the sale, the director owned 7,529 shares in the company, valued at $240,928. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Karimah Es Sabar also recently made the following trade(s):
- On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.03, for a total transaction of $1,667,397.05.
- On Tuesday, March 31st, Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.17, for a total transaction of $1,848,365.05.
Capricor Therapeutics Price Performance
Shares of NASDAQ CAPR opened at $32.11 on Friday. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -14.21 and a beta of 0.48. Capricor Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $40.37. The firm has a 50-day moving average price of $27.38 and a 200 day moving average price of $19.01.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Equities research analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.
Key Stories Impacting Capricor Therapeutics
Here are the key news stories impacting Capricor Therapeutics this week:
- Positive Sentiment: Several brokerages have raised targets or issued overweight/buy ratings (Cantor Fitzgerald $62, Piper Sandler $58, Maxim $50), supporting upside expectations versus the consensus. Analyst Coverage
- Neutral Sentiment: One director sale (7,529 shares at $32.00) was executed under a pre‑arranged Rule 10b5‑1 plan, which typically mutes the negative signal from insider selling but does not eliminate market concern. SEC Filing
- Neutral Sentiment: Institutional ownership is modest (~21.7%) with a few small new positions reported — indicates some institutional interest but not large-scale conviction yet. Institutional Holdings
- Negative Sentiment: CFO Anthony Bergmann sold 25,000 shares on March 31 at an average $30.13 (disclosed in an SEC Form 4), reducing his direct holding by ~75% — a sizable insider reduction that may worry investors about near-term outlook or personal liquidity needs. CFO Sale Filing
- Negative Sentiment: Director Karimah Es Sabar sold large blocks across March 31–April 1–2 (61,265 @ $30.17; 53,735 @ $31.03; plus a 7,529 @ $32.00 sale under a 10b5‑1 plan). Combined insider disposals this week total roughly 148k shares for several million dollars — a significant decrease in insider ownership that can pressure sentiment. Director Sale Filing
- Negative Sentiment: Capricor missed Q4 EPS estimates (reported -$0.62 vs. consensus -$0.51 on March 12), which is a near-term fundamental negative that analysts and investors will weigh against bullish price targets. Earnings Report
Analysts Set New Price Targets
Several equities analysts recently weighed in on CAPR shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Capricor Therapeutics in a research note on Monday, December 29th. UBS Group set a $50.00 target price on Capricor Therapeutics in a research report on Monday, December 15th. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, January 11th. Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the company an "overweight" rating in a research report on Friday, March 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, March 10th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $46.09.
View Our Latest Report on Capricor Therapeutics
Institutional Investors Weigh In On Capricor Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC acquired a new position in shares of Capricor Therapeutics in the third quarter valued at approximately $28,000. Parkside Financial Bank & Trust purchased a new position in shares of Capricor Therapeutics during the third quarter valued at approximately $36,000. Russell Investments Group Ltd. boosted its position in Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 2,786 shares during the last quarter. ACT Capital Management LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth approximately $43,000. Finally, GoalVest Advisory LLC purchased a new stake in Capricor Therapeutics in the 4th quarter worth approximately $59,000. Hedge funds and other institutional investors own 21.68% of the company's stock.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
